נכסים נקיים למניה בודדת enGene Holdings Inc (ENGN)

This daily price chart for enGene Holdings Inc. (ENGN) is subject to the impact of production scaling complexities and FDA inspections, with the metric currently at 3.43. The business is based on the implementation of a non-viral gene delivery method to combat bladder tumors. The company's growth relies on the uniqueness of its technological platform and the potential for collaboration with major medical behemoths.

For enGene Holdings Inc. (ENGN), whose valuation is based on gene therapy patents, the book value per share determines the residual capital of the business after all liabilities are settled. This metric measures the actual value of net assets, allowing an investor to identify fundamental support levels and assess the risk of overpaying for the security through the visualization of the book value per share.